Fig. 6

Olaparib combined with ML216 demonstrates enhanced anti-tumor effect on PC3 xenografts in vivo. A Representative images of PCa tumor xenografts from each mouse (n = 6/group). B, C The tumor weight and volume of each group were recorded and analyzed. D The body weights of mice were measured for 26 days. E, F The weight of main organs was measured and analyzed after sacrifice. G IHC of Ki-67 was performed on tumor tissue and quantified using Image software. Scale bars: 100 μm. H Representative images of H&E staining. Scale bars: 100 μm. I Schematic illustration depicting the upregulation of BLM expression by knockdown of PARP1 or interacted with HSP90AB1 and the superior anti-tumor effect observed with the combination of olaparib and ML216. Shown are the means ± SD from 3 experiments (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, and “ns” indicated no significant difference)